introduction
In advanced non-small-cell lung cancer (NSCLC) patients, the backbone treatment is based on a platinum-based doublet therapy that yields better overall survival (OS), quality of life (QoL) and control of symptoms than best supportive care (BSC) [1] . Historical median OS after first-line treatment is 8-10 months, with a 1-year survival rate of 33% and a progression-free survival (PFS) of 3-5 months [2] [3] [4] [5] . The last decade has seen a considerable change in the field of systemic treatment.
First, the molecular characterisation of lung cancer has lead to the approval of targeted therapies that improve PFS, response rate and QoL in small subsets of patients. These targeted treatments include epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) (erlotinib or gefitinib) if the tumour harbours an EGFR-activating mutation, and the anaplastic lymphoma kinase (ALK) inhibitor crizotinib for tumours with ALK rearrangements [6] [7] [8] .
Moreover, the platinum-based doublet can be optimised by adding bevacizumab (Avastin®, Roche). This approach has been shown to improve PFS in selected patients with non-squamous NSCLC [9] .
The benefits on OS of second-line single-agent drugs (pemetrexed, docetaxel or EGFR-TKI) have also been validated ( Figure 1 ) [2, 6, 7, [10] [11] [12] .
For years, attention has focused on prolonging first-line therapy benefit, in a strategy described as the 'maintenance' strategy. The prolongation of one or more of the drugs used in the first-line treatment (continuation maintenance) or the introduction of another agent with no cross-resistance (switch maintenance or early second-line) is designed to improve PFS and OS with minimal toxicity and no adverse effects on patient QoL ( Figure 2) . The meta-analysis of Soon et al. showed that extending chemotherapy beyond a standard number of cycles was associated with a significant improvement in PFS; however, this meta-analysis includes studies with heterogeneous trial designs and it is based on published results [13] . Table 1 summarises the drugs used for maintenance therapy in NSCLC according to the indications approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to date.
continuation maintenance therapy
There is no strong biological evidence to support continuation maintenance therapy, and the issue of the optimal duration of first-line therapy has yet to be resolved. The first studies on maintenance therapy assessed the benefits of continuing the first-line regimen beyond two to four cycles, until progression. Subsequent studies then tested maintenance therapy with a single cytotoxic agent, as a way of improving tolerance and the toxicity profile. Table 2 reports the results of trials investigating continuation maintenance therapy with cytotoxic agents. Several studies have evaluated the efficacy benefits of adding a targeted agent to first-line chemotherapy (Table 3 ). The benefits observed in some of these trials could be attributed to the concomitant treatment phase and the maintenance phase; these studies will, therefore, not be considered further here.
continuation maintenance therapy with cumulative toxicity Buccheri et al. [14] assigned patients with stable disease (SD) after two or three cycles of methotrexate/doxorubicin/ cyclophosphamide/lomustine to two groups: maintenance therapy with the same regimen or observation. No clinical benefits of maintenance therapy were observed in terms of either OS or time to progression (TTP), and tolerance and toxicity were significantly worse in the maintenance therapy group.
In a small study (N = 230), Socinski et al. [15] reported no clinical advantage from extending the duration of carboplatin/ paclitaxe (Taxol®, Bristol-Myers Squibb) therapy beyond four cycles, and the occurrence of significant cumulative toxicity resulting in peripheral neuropathy: 14% of patients receiving four cycles of chemotherapy experienced grade 2-4 neuropathy, versus 27% of patients randomly assigned to the continuous therapy group.
In a phase II trial evaluating induction therapy with different schedules of carboplatin/pacliatxel, patients with a complete or partial response (CR or PR) or SD after 16 weeks were randomly assigned to two groups: maintenance therapy with weekly paclitaxel or observation. Median TTP and median survival time were 38 and 75 weeks, respectively, in the maintenance arm and 29 and 60 weeks, respectively, in the observation arm. During maintenance therapy, 45% of patients experienced at least one grade 3 or 4 adverse event. The small size of the sample limits the interpretation of this benefit observed (130 (33%) of the 390 patients receiving the induction therapy attended the maintenance phase) [16] .
continuation maintenance therapy with non-cumulative toxicity gemcitabine. Three studies have compared the efficacy of gemcitabine maintenance therapy plus BSC with that of BSC alone, in patients without disease progression (DP) after four [17] After four cycles of first-line therapy 2.1 months P = 0.172
1.6 months (TTP) P < 0.001 Belani et al. [18] After four cycles of first-line therapy −1.3 months P = 0.84 0.1 months NR Pérol et al. [19] After four cycles of first-line therapy 1.3 months P = 0.3867
1.9 months P < 0.001 Pemetrexed PARAMOUNT [20, 21] After four cycles of first-line therapy 2.9 months P = 0.0195
1.6 months P < 0.001 AVAPERL [22, 23] After four cycles of first-line therapy 3.9 months P = 0.29 3.7 months P < 0.001 a Statistically significant results are shown in bold.
cycles of first-line chemotherapy with a platinum compound/ gemcitabine. In the phase III trial of the Investigators of Central European Cooperative Oncology Group (CECOG), 215 (61%) of 354 enrolled patients were randomly assigned. The primary objective was achieved, with a median TTP of 3.6 months in the gemcitabine arm versus 2.0 months in the BSC arm (P < 0.001). OS was slightly, but not significantly, longer for gemcitabine maintenance. Subgroup analyses revealed that OS was significantly better only for the patients in the gemcitabine arm with a good PS at baseline. QoL and access to second-line treatment were similar in all patients of both arms. This study was subject to several limitations. First, 22% of the gemcitabine cycles within the maintenance period were delayed, potentially delaying restaging and, thus, affecting TTP comparisons between the two arms. Secondly, a chest X-ray was allowed for tumour assessment, and the Southwest Oncology Group criteria were used. The median number of cycles of gemcitabine during maintenance therapy was only 3 (range 0-38) [17] .
In a subsequent phase III trial, 255 of the 519 patients enrolled (49%) were randomly allocated to gemcitabine therapy and observation groups, and no improvement in PFS or OS ( primary end point) was observed. This trial may have been inconclusive due to the high proportion of patients with a PS of two or more (25%) at baseline [18] .
In the three-arm IFTC-GFPC 0502 study, 834 patients received first-line therapy. Of these, only 464 (56%) patients did not progress and entered the maintenance phase: 154 (18%) were randomly allocated to the gemcitabine arm versus 155 (19%) to the observation arm. Median PFS, the primary end point of the study, was 3.8 and 1.9 months, respectively, for these two arms. However, this statistically significant increase in PFS did not translate into a clear benefit in terms of OS, although the trial was underpowered for OS analysis. In the gemcitabine arm, a trend toward a greater PFS and OS benefit was observed in patients with an objective response after first-line therapy [19] .
pemetrexed (Alimta®, Eli Lilly and Company). The phase III PARAMOUNT trial evaluated whether pemetrexed maintenance therapy resulted in a better PFS than placebo in patients with nonsquamous NSCLC displaying disease control after four cycles of cisplatin/pemetrexed. In total, 939 patients were enrolled and 539 (57%) were randomly assigned. Pemetrexed significantly Carboplatin/paclitaxel (six cycles) 250 mg Gefitinib 500 mg Gefitinib −0.1 months P = 0.6385 −1.2 months P = 0.6385 −0.4 months (TTP) P = 0.0562 0.3 months (TTP) P = 0.0562 TRIBUTE [26] Carboplatin/paclitaxel (six cycles) Erlotinib 0.1 months P = 0.95 0.2 months (TTP) P = 0.36 TALENT [27] Cisplatin/gemcitabine (six cycles) Erlotinib −1.1 weeks P = 0.49 −0.9 weeks (TTP) P = 0.74 ESCAPE [28] Carboplatin/paclitaxel (six cycles) Sorafenib 0.1 months P = 0.915 −0.8 months P = 0.433 NEXUS [29] Cisplatin/gemcitabine (six cycles) Sorafenib −0.1 months P = 0.401 0.5 months P = 0.008 ECOG 4599 [30] Carboplatin/paclitaxel (six cycles) Bevacizumab 2.0 months P = 0.003
1.7 months P < 0.001 AVAIL [31, 32] Cisplatin/gemcitabine (six cycles) High-dose bevacizumab Low-dose bevacizumab 0.3 months P = 0.761 0.5 months P = 0.420 0.4 months P = 0.03 0.6 months P = 0.003 FLEX [33] Cisplatin/vinorelbine (six cycles) Cetuximab 1.2 months P = 0.044
Carboplatin/taxane (six cycles) Cetuximab The final OS data confirmed the statistically significant benefit for the pemetrexed arm (P = 0.0195). A subgroup analysis suggested that patients benefited from pemetrexed, regardless of the response to induction therapy. Surprisingly, in the placebo arm, the group of patients displaying CR/PR after induction therapy had a median PFS of 2.6 (1.6-2.9) months, whereas the median PFS of the patients with SD was 3.0 (2.8-4.1) months. The final analysis reported a median OS identical between the SD placebo subgroup and the CR/PR placebo subgroup. Patients received a median of four cycles (range 1-16) of pemetrexed. The patients in the pemetrexed arm experienced a significantly higher incidence of drug-related grade 3-4 anaemia, neutropenia and fatigue, but no significant difference in QoL was observed between the two arms of the study. Second-line therapy was administered to 64% of the patients in the pemetrexed group and 72% of those in the placebo group [20, 21] . The AVAPERL phase III trial resembled the PARAMOUNT trial, but with the addition of bevacizumab in both the treatment groups. After four cycles of first-line chemotherapy with cisplatin/pemetrexed/bevacizumab, 67% of the patients were randomly assigned to treatment groups receiving bevacizumab alone or bevacizumab plus pemetrexed. During the maintenance phase, patients received a median of five cycles of therapy in the bevacizumab arm and a median of seven cycles of therapy in the bevacizumab plus pemetrexed arm. The primary end point was met, with PFS from randomisation time of 7.4 months in the two-drug arm versus 3.7 months in the bevacizumab-alone arm (P < 0.001). The study was not powered for OS, but the data obtained suggest a possible trend towards improvements in OS in the bevacizumab plus pemetrexed arm. Adverse events were noticed more frequently in the bevacizumab plus pemetrexed group, but a preliminary analysis found no significant difference in QoL between the two arms. Subsequent treatment was administered to 57% of patients in the bevacizumabalone group and 39% of patients in the two-drug arms [22, 23] .
The PointBreak study compared a regimen similar to the best arm of the AVAPERL trial (carboplatin/pemetrexed/bevacizumab followed by pemetrexed/bevacizumab) with the first combination including bevacizumab to be evaluated in a phase III trial, carboplatin/paclitaxel/bevacizumab followed by bevacizumab. Pre-specified exploratory non-comparative analyses of the maintenance population showed that OS was 17.7 months in the pemetrexed group and 15.7 months in the paclitaxel group, with PFS values of 8.6 and 6.9 months, respectively. However, the induction phase population was randomised, whereas the maintenance population was a post-randomisation population. The differences between the two populations may have influenced the outcome of the maintenance regimens [35] .
comments on continuation maintenance therapy
The optimal duration of first-line treatment has long been debated. According to the European Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) guidelines, the initial chemotherapy should be stopped after four cycles in patients who are not responding to therapy, and no more than six cycles should be given, even to patients who have responded to treatment [36] [37] [38] . This recommendation is based on several studies showing an absence of benefit of longer treatment duration, in terms of OS and QoL. Smith et al. [39] reported no significant clinical benefit from prolonging chemotherapy with cisplatin/mitomycin C/vinblastine from three to six cycles. In the trail carried out by von Plessen et al. [40] , patients were randomly assigned to two groups: three or six cycles of carboplatin/vinorelbine. No difference was found between these two groups in terms of OS and QoL. Only one randomised phase III trial has formally compared four and six cycles of a third-generation regimen in Asian patients displaying no DP after two cycles. In this trial, Park et al. [41] showed that TTP was longer in patients undergoing six cycles than in those undergoing four cycles, but this did not translate into survival benefits, probably because 63% of the six-cycle group and 74% of the four-cycle group received second-line therapy with gefitinib, which is known to be more effective in Asian patients, between courses of treatments. All randomised phase III trials leading to the approval of new systemic treatments since last years have been based on six cycles of chemotherapy, which is, thus, logically considered to be the standard number [4, 12, [30] [31] [32] . Figure 3 shows the median number of cycles administered in the many studies carried out to date [4, 12, 15, 17, 19, [20] [21] [22] [23] [30] [31] [32] .
switch maintenance (or early second-line)
There is compelling evidence to suggest that intratumoral heterogeneity plays a role in drug resistance, particularly in later stages of tumour progression. Genetically different subpopulations of tumours cells are present, and first-line therapy should destroy the predominant subpopulations. Thus, switch maintenance therapy with a different active agent aims to hit clonal variants resistant to the first-line therapy and likely to cause DP, before they have had time to increase in number. Such treatment would be expected to confer a survival advantage over the treatment of patients at the time of progression. Table 4 reports the results of trials evaluating switch maintenance therapy.
switch maintenance (early second-line) therapy with cumulative toxicity vinorelbine. Westeel et al. compared vinorelbine maintenance therapy with observation in 181 patients who responded to first-line chemotherapy with cisplatin/mitomycin C/ifosfamide (four cycles) or chemoradiation (two cycles of chemotherapy plus thoracic radiotherapy). Patients with SD after induction therapy were not included. Crossover was not allowed, so the patients in the observation group could not be treated with vinorelbine at any time. No improvement in terms of PFS or OS was observed, and treatment was stopped in 21% of the patients, due to toxicity [42] .
docetaxel (Taxotere®, Sanofi-Aventis). In the phase III trial carried out by Fidias et al., patients without progression after four cycles of first-line therapy with carboplatin/gemcitabine were randomly assigned to receive docetaxel either immediately after first-line therapy until DP (up to six cycles) or not until the onset of DP. Of the 566 patients enrolled, 309 (55%) were randomly assigned to these two groups. The study showed a statistically significant improvement in PFS (P = 0.0001) and a nonsignificant trend toward improvement in OS for the immediate docetaxel treatment arm (12.3 versus 9.7 months). However, only 62.8% of the patients in the delayed docetaxel group received at least one cycle of docetaxel therapy, and the OS for these patients was 12.5 months, identical to that for the immediate docetaxel arm. Thus, the observed difference in terms of OS resulted mostly from differences in the percentages of patients receiving the treatment. The major reasons for patients not receiving docetaxel in the delayed treatment arm were DP and patient choice. Additional analysis showed that patients may have experienced a deterioration of their symptoms, rendering them ineligible for second-line therapy. Furthermore, patients in the control arm underwent disease assessment every 3 months, whereas those in the experimental arm underwent disease evaluations every two Trials evaluating first-line therapy followed by maintenance therapy Figure 3 . The median number of treatment cycles administered in trials evaluating first-line therapy without maintenance therapy and in trials evaluating first-line therapy followed by continuation maintenance treatment. After two to four cycles of first-line therapy 0 months P = 0.65 2.0 months P = 0.11 Docetaxel Fidias et al. [43] After four cycles of first-line therapy 2.6 months P = 0.0853 3.0 months P = 0.0001 Pemetrexed Ciuleanu et al. [44] After four cycles of first-line therapy 2.8 months P = 0.012 1.7 months P < 0.0001 Erlotinib SATURN [45] After four cycles of first-line therapy 1.0 months P = 0.0088
1.2 months P < 0.0001 ATLAS [46, 47] After four cycles of first-line therapy 2.0 months P = 0.2686
1.1 months P = 0.0012 Pérol et al. [19] After four cycles of first-line therapy 0.6 months P = 0.3043
1.0 months P = 0.003 Gefitinib Takeda et al. [48] At inclusion 0.8 months P = 0.11 0.3 months P < 0.001 Gaafar et al. [49] After two-six cycles of first-line therapy 1.5 months P = 0.2 1.2 months P = 0.0015 Zhang et al. [50] After four cycles of first-line therapy 1.8 months P = 0.26 No statistically significant differences in terms of QoL were observed between the patients of the two arms of this study [43] .
months
switch maintenance (early second-line) therapy without cumulative toxicity pemetrexed. In the trial carried out by Ciuleanu et al., 663 NSCLC patients without progression after four cycles of platinumbased chemotherapy (not including pemetrexed) were randomly assigned to receive pemetrexed as maintenance therapy or placebo until DP. The median number of maintenance cycles delivered in the pemetrexed arm was 5. Median PFS and OS were significantly higher in the pemetrexed group (P < 0.0001), particularly in patients with a non-squamous histology. The frequency of grade 3 and 4 toxic effects was significantly higher in the pemetrexed arm. The authors reported that pain and haemoptysis symptoms worsened significantly later in the patients of the pemetrexed group. Systemic post-discontinuation therapy was administered to 51% of patients in the pemetrexed arm and 67% of patients in the placebo arm. The type of treatment administered was left to the investigator's discretion, and the rate of crossover to pemetrexed for the placebo group was only 18% [44] .
erlotinib. In the SATURN study, unselected patients with NSCLC with disease control after four cycles of standard platinum-based therapy ( pemetrexed and bevacizumab were not permitted) were enrolled. Of the 1949 patients included, 889 (46%) were randomly assigned to the erlotinib maintenance or placebo groups. This study documented a modest, statistically significant improvement in PFS [12.3 versus 11.1 weeks; hazard ratio (HR) = 0.71, P < 0.0001]. PFS was significantly greater on erlotinib maintenance, both in patients with EGFR mutations [HR = 0.10, 95% confidence interval (CI) 0.04-0.25] and in those with wild-type EGFR tumours (HR = 0.78, 95% CI 0.63-0.93, P = 0.0185): median PFS was not reported, but the difference for patients without EGFR-activating mutations appeared to be very modest, based on the PFS curve obtained.
OS was moderately, but significantly higher in the experimental arm (12.0 versus 11.0 months; HR = 0.81, P = 0.0088). In particular, Cappuzzo et al. showed that patients with SD after first-line therapy seemed to experience more pronounced benefits, in terms of OS, on erlotinib maintenance treatment than did those with CR or PR. In both the arms, 71%-72% of patients received subsequent treatment, but only 21% of the patients in the placebo arm received erlotinib. No differences in QoL were observed [45] . The ATLAS study compared bevacizumab maintenance therapy with bevacizumab plus erlotinib maintenance therapy in patients displaying no DP after four cycles of a bevacizumab plus platinum-based regimen. The addition of erlotinib to bevacizumab improved PFS (4.8 versus 3.7 months, P = 0.0012), with no meaningful effect on OS. The number of patients harbouring EGFR mutations was not reported [46, 47] .
In the IFTC-GFPC 502 study, switch maintenance therapy with erlotinib significantly improved PFS, but not OS: the median PFS of the 155 patients (19%) randomly assigned to erlotinib was 2.9 months, whereas that for the observation group was 1.9 months. As discussed above, this study was not powered for the assessment of statistically significant differences in survival. EGFR mutation status could be evaluated in only 41% of the patients, too few for further analysis. According to the protocol, the patients in all three arms received pemetrexed at DP [19] .
gefitinib. Three studies have assessed the benefits of gefitinib administration immediately after first-line therapy in unselected NSCLC patients.
In the West Japan Thoracic Oncology Group Trial, 604 patients were randomly assigned to receive platinum-doublet chemotherapy for up to six cycles or sequential gefitinib after three cycles of chemotherapy in the absence of DP. The median number of chemotherapy cycles was 3 in both arms; only 57.3% of the patients in the experimental arm were treated with gefitinib after the three cycles of chemotherapy. Median OS, the primary end point, was 12.9 months in the chemotherapy-only Annals of Oncology reviews group and 13.7 months in the gefitinib group (not significant); PFS was significantly longer in the gefitinib group (4.3 versus 4.6 months, respectively, HR = 0.68, 95% CI 0.57-0.80, P < 0.001). A statistically significant difference in OS between the two arms of the study was observed in patients with adenocarcinoma histology. EGFR mutation status was not assessed in this study. In the chemotherapy arm, the rate of crossover to EGFR-TKI treatment was only 54.5%. No differences in QoL were observed [48] . A study by EORTC was stopped early due to poor accrual (only 173 patients). Patients not progressing after two to six cycles of platinum-based therapy were included. The required number of events for assessing OS was not reached, but a statistically significant improvement in PFS was observed (HR = 0.61, 95% CI 0.45-0.83, P = 0.0015). In the gefitinib group, 57% of the patients had adenocarcinoma histology compared with 46% in the placebo group; the number of patients EGFR mutated is not available. EGFR-TKI was administered as a post-study treatment to 40% of the patients in the placebo arm [49] .
In the INFORM study, 296 Chinese patients without progression after four cycles of first-line platinum-based chemotherapy were randomly assigned to the gefitinib or placebo group. Patients of known EGFR status were excluded, to prevent a selection bias. PFS, the primary end point, was significantly longer in the group of patients treated with gefitinib than in those receiving placebo (4.8 versus 2.6 months, P < 0.0001), whereas OS was not significantly greater. EGFR status could be assessed retrospectively in only 27% of patients, and 30 (38%) with EGFR-activating mutations were evenly distributed between the two arms. The authors reported that the benefit of gefitinib, in terms of PFS, was not statistically significant in the subgroup without EGFR mutations. QoL was significantly better for the patients in the gefitinib arm. The post-study treatment was administered to 62% of the patients in the placebo group and 43% of those in the gefitinib arm, but only 29% received EGFR-TKI [50] .
comments on switch maintenance therapy
In most studies, post-study treatment included a drug approved for use in the second-line setting, but the trial reported by Fidias et al. is the only one, to date, in which the switch therapy (docetaxel) had to be used as the post-study treatment at the time of DP in the control arm. OS was identical for the patients receiving docetaxel in the delayed treatment arm, so the key issue is the 62.8% of patients able to receive a second-line therapy at DP [43] . Pérol et al. reported that 91% of the patients in the observation group were able to receive second-line therapy at DP, a figure much higher than the 62%-76% reported in most studies [19, 44, 45, [48] [49] [50] . The design used in the study by Fidias et al. made it possible to compare an early second-line strategy with a conventional approach (second-line treatment at the time of DP). In the other studies, several different drugs were allowed as post-study treatment, so the effect of the strategy cannot be isolated from that of the drug used. Figure 4 illustrates the treatments given to the patients in the control arm at DP [19, [43] [44] [45] [48] [49] [50] .
Only two of the trials evaluating the use of EGFR-TKI for maintenance therapy reported the EGFR mutation status.
Cappuzzo et al. reported a significant benefit in terms of PFS in both patients with EGFR mutations and those with wild-type EGFR tumours but with different HR values, as reported above. No OS data were reported for the EGFR mutation-positive subgroup, because most patients had yet to experience an event. Moreover, most of the patients with EGFR mutations in the placebo group were subsequently treated with EGFR-TKI [45] . In the INFORM trial, no significant difference in PFS was found between the two arms for the subgroup of patients with wildtype EGFR tumours [50] . In conclusion, the benefits of EGFR-TKI maintenance therapy have yet to be established for the population of patients with wild-type EGFR tumours. No proper trial evaluating the optimal number of cycles of platinumbased therapy with a 'third-generation' compound has yet been carried out. In all maintenance trials, patients were randomly assigned after four cycles of first-line therapy. No study has compared six cycles of induction therapy plus observation until DP with four cycles of induction therapy plus a maintenance phase in terms of PFS, OS, QoL and safety profile. The clinical benefit of maintenance therapy as a function of response to first-line therapy has not yet been evaluated. In several studies, the percentage of patients receiving subsequent therapy at DP was low, given that the patients to be randomised immediately before the maintenance phase had to be fit for treatment [20-23, 44, 45, 48-50] . Only one study showed a significant difference in QoL [50] Thus, QoL was not adversely affected by maintenance therapy toxicity, but a longer PFS did not improve QoL either. In most studies of continuation maintenance therapy, no improvement in OS was documented, whereas a statistically significant increase in PFS was observed [17, 19, 22, 23] . Only the PARAMOUNT trial reported significant improvements in both PFS and OS, in the pemetrexed maintenance arm [20, 21] . In the experimental arm of trials evaluating the benefit of adding a targeted agent to standard first-line therapy, the targeted drug was continued as maintenance therapy until DP. However, the design of these studies makes it impossible to draw conclusions about the benefits of maintenance therapy [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Crossover was integrated into the study design for patients in the control arm at the time of DP in only one trial evaluating the benefit of early second-line treatment; in this trial, no benefit in terms of OS was observed [43] . Only two trials evaluating the benefit of early second-line treatment reported a significant increase in OS; in these studies, only 18%-21% of patients in the control arm received the study agent [44, 45] . In the trials evaluating EGFR-TKI as an early second-line treatment, subgroup analyses highlighted a significant interaction between EGFR status and benefit in terms of PFS and OS [45, 50] .
PFS, progression-free survival; OS, overall survival; QoL, quality of life; DP, disease progression; EGFR-TKI, epidermal growth factor receptor tyrosine-kinase inhibitor.
which patients are the best candidates for maintenance therapy?
The results of these trials may enable us to develop a description of the patients most likely to benefit from maintenance therapy.
The following criteria could be used to select potential maintenance treatment:
• Toxicity profile in first-line treatment: in the face of poor tolerance to platinum compounds, it might be reasonable to stop the platinum-doublet regimen and to continue with a single agent in maintenance therapy. The choice of the maintenance agent should take into account the residual toxicities after first-line therapy.
• PS after first-line therapy: in the only trial in which patients with a PS of 2 were enrolled, no clinical benefit was observed [18] .
• Patient preference when faced with the option of being always under treatment, with no treatment holiday.
• Histology: the trial carried out by Ciuleanu et al. reported PFS and OS to be better with pemetrexed mostly in patients with non-squamous tumours [44] .
• Molecular profile of the disease: in clinical trials testing EGFR-TKI as first-line therapy, subgroup analysis also revealed the response rate to chemotherapy to be higher in patients with an EGFR mutation than in those with wild-type EGFR [6] . It therefore appears likely that patients with EGFR mutations would benefit from maintenance therapy with cytotoxic agents. The benefits of early second-line treatment with EGFR-TKI in EGFR wild-type population remain to be clearly demonstrated; an analysis within the TAILOR trial showed that docetaxel is more effective in terms of PFS (P = 0.02) and OS (P = 0.05) than erlotinib for patients who had wild-type EGFR tumours [51] . It has been suggested that patients harbouring tumours with ALK translocation have a higher rate of response to pemetrexed, but this remains to be confirmed [8] .
• Response to first-line therapy: in the SATURN trial, the authors reported an advantage of maintenance therapy in patients with SD after first-line therapy [45] . Clonal variants of tumour cells resistant to first-line therapy could be responsible for the lack of response to treatment and for subsequent DP. Viewed in this light, early second-line treatment may be clinically advantageous. No other studies have documented statistically significant differences in efficacy as a function of the response to first-line therapy.
conclusions
Based on the available results of trials evaluating maintenance treatment, this strategy for treating advanced NSCLC patients should be considered in limited subgroups of patients. Only one trial of continuation maintenance treatment has shown a significant increase in both PFS and OS and no difference in QoL [20, 21] . For switch maintenance therapy, the only correctly designed trial carried out to date found no clinical benefit [43] . Moreover, the issue on the optimal number of cycles of first-line therapy remains to be resolved (Table 5) . Table 6 reports the principal randomised trials evaluating maintenance therapy currently underway.
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